19 June 2013
Keywords: tautatis, lead, compound, work, pd, well, ad
Article | 23 March 2009
US drug developer TauTaTis says that its lead compound for inhibition of tau protein pathology, the specific neurodegenerative process in
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
23 March 2009
27 March 2009
18 June 2013
© 2013 thepharmaletter.com